logo
A 43,000 year-old work of art? Neanderthals may have painted portraits.

A 43,000 year-old work of art? Neanderthals may have painted portraits.

USA Today4 days ago

A 43,000 year-old work of art? Neanderthals may have painted portraits. An ancient granite pebble included indentations resembling a face, its nose a red dot. A study says it may have had symbolic significance.
Show Caption
Hide Caption
Tourist climbs sacred Mayan pyramid in Mexico
A German tourist was escorted from an archaeological complex when he climbed and attempted to evade security at a Mayan pyramid in Mexico.
An eight-inch rock found at an archaeological site in central Spain is the latest indication that Neanderthals were making art long before modern humans, further eroding stereotypes of the extinct species as dull-witted.
The July 2022 discovery at San Lázaro rock-shelter in Segovia, described as 'exceptional' by the authors of a paper published May 25 in the journal Archaeological and Anthropological Sciences, dates back 43,000 years – long before modern humans inhabited the area.
The quartz-rich granite pebble included indentations resembling a face, its nose a Rudolph-like red dot visible at center. Significantly, the spot didn't appear to be random, instead bearing evidence indicating it was the product of someone's imagination.
'The ocher dot does not appear as a shapeless addition or a mere stain,' wrote lead author David Álvarez-Alonso of Madrid's Complutense University. 'Rather, it contains a fingerprint that implies the pigment has been applied specifically with the tip of a finger soaked in pigment.'
The authors consider the artifact a nonutilitarian visual symbol – in other words, not a tool but an altered or marked object with possible symbolic significance. While its age makes it impossible to draw any definitive conclusions, they wrote, the stone could 'represent one of the oldest known abstractions of a human face in the prehistoric record."
'The fact that the pebble was selected because of its appearance and then marked with ocher shows that there was a human mind capable of symbolizing, imagining, idealizing and projecting his or her thoughts on an object,' they wrote.
An expanding Neanderthal portfolio
This isn't the first time a Neanderthal fingerprint has been pinpointed, the authors noted. A partial one, likely made by a thumb, was found on resin discovered in Germany in 1963.
However, the discovery offers yet another dab of evidence suggesting that Neanderthals made art. In 2018, The Guardian reported archaeological findings in Spain indicating that Neanderthals used red ocher to produce shapes and symbols on cave walls 65,000 years ago.
The species flourished from roughly 350,000 to 40,000 years ago, and studies indicate they and modern humans may have gone their separate ways as long as 800,000 years ago.
Increasing evidence has indicated that Neanderthals were more advanced than once thought.
In 2020, a paper published in the journal Science said evidence found in a coastal cave in Portugal suggested Neanderthals were skilled fishermen who regularly consumed seafood as part of their diet. Until then, only humans (Homo sapiens) had been thought to look to the sea as a food source.
Meanwhile, the discovery of 176,000-year-old structures deep within a French cave hinted at Neanderthals' ability to use fire and work in groups. A 2016 article in Nature described strange, circular edifices constructed in an interior space 360 yards removed from daylight; the formations were made from uniform stalagmites, many of them cut to size.
With the earliest known human-built structures 40,000 years old, the cave formations not only predate such activity by Homo sapiens but also show Neanderthal utilization of deep caves began much earlier as well. According to the study, the earliest indications of modern humans using deep caves are less than 42,000 years old.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Trump administration reportedly tightens the reins on Veterans Affairs scientists
The Trump administration reportedly tightens the reins on Veterans Affairs scientists

Yahoo

time6 hours ago

  • Yahoo

The Trump administration reportedly tightens the reins on Veterans Affairs scientists

Last week, Health Secretary Robert F. Kennedy Jr. warned that the Trump administration might crack down on government scientists contributing to medical journals and instead create 'in-house' medical publications. And it seems the administration is wasting no time in moving forward. According to The Guardian, the administration essentially tongue-lashed two Department of Veteran Affairs scientists via email after they co-authored a report — published in the New England Journal of Medicine — highlighting how federal cuts could negatively affect patients' health. Basically, the two scientists, Texas-based pulmonologists Pavan Ganapathiraju and Rebecca Traylor, said cuts at their agency could have disastrous effects on veterans' respiratory health. And that didn't go over well with their bosses. The Guardian reported: The edict, laid down in emails on Friday by Curt Cashour, the VA's assistant secretary for public and intergovernmental affairs, and John Bartrum, a senior adviser to VA secretary Doug Collins, came hours after the prestigious New England Journal of Medicine published a perspective co-authored by two pulmonologists who work for the VA in Texas. 'We have guidance for this,' wrote Cashour, a former Republican congressional aide and campaign consultant, attaching the journal article. 'These people did not follow it.' The Guardian reported further: The article sparked an immediate rebuke from Trump's political appointees, according to internal emails obtained by the Guardian. 'We have noticed a number of academic articles and press articles recently,' Bartrum wrote, attaching a copy of the journal article. 'Please remind the field and academic community that they need to follow the VA policy.' Cashour, the assistant secretary, wrote that approval for publication in national media was delegated to his office. Local and regional directors were to inform Washington 'as soon as possible' when situations exist 'that have the potential for negative national exposure'. The issue here seems obvious. I think Americans should want experts working for them who can offer scientifically based critiques or recommendations on U.S. policy, especially if their work is laid out sanely in a respected medical journal. The idea of such views potentially being suppressed not out of primary concern for public health but rather 'the potential for negative national exposure,' as Bartrum suggested in his email, is worrisome. This kind of restriction seems to fit within the administration's broader attack on scientific expertise, such as its rescission of federal research grants that is driving some scientists out of the country. The VA's press secretary, Peter Kasperowicz, said in a statement to MSNBC that requiring approval for contributions to medical journals is 'VA policy that has been in place for several years across both Democrat and Republican administrations' and 'requires VA employees to properly coordinate with public affairs staff prior to speaking with the media.' He added that 'virtually every organization both inside and outside government has similar policies.' That claim was disputed by one of the authors, Ganapathiraju, who said his co-authored article was in full compliance and that VA rules encourage — but don't require — coordination with public affairs professionals at the agency. It certainly looks like the Trump administration is engaging in academic censorship. And the fact that the administration's major 'in-house' health report has been a complete disaster doesn't exactly paint this White House as trustworthy on the matter of scientific research. This article was originally published on

Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug

Yahoo

time10 hours ago

  • Yahoo

Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug

Bristol-Myers Squibb (NYSE:BMY) is doubling down on its oncology ambitions with a deal that could reach $11.1 billion, partnering with BioNTech (NASDAQ:BNTX) to co-develop a next-generation cancer therapy known as BNT327. The German biotech will receive $1.5 billion upfront, $2 billion in staggered payments through 2028, and stands to gain another $7.6 billion if clinical and commercial milestones are met. Both companies will share development costs and future profits. The deal reflects growing urgency among pharma giants to replenish their pipelines, as legacy blockbusters face generic competition. Bloomberg Intelligence estimates this class of immunotherapy drugs could generate $60 billion annually by 2027. BNT327's backstory adds intrigue. BioNTech originally licensed the compound from Chinese biotech Biotheus in 2023 before acquiring the company outright for up to $950 million. It's now positioning the therapy as a core asset in its oncology portfolio. While early trial data suggests Pfizer's competing drug may show stronger efficacy, BioNTech is further along in developing broader cancer indications. The approach behind these drugs is evolving fastmerging immunotherapy with anti-angiogenesis mechanisms to cut off tumors' blood and oxygen supply. This model gained traction after Akeso and Summit Therapeutics' combination therapy showed promising results against Merck's Keytruda in a major Chinese trial. Still, the bar remains high. These new therapies haven't yet demonstrated a consistent survival advantage over standard treatments, and head-to-head data outside China could take years. For BioNTech, though, this deal marks a decisive return to its original focuscancerafter riding a pandemic-era wave with its COVID-19 vaccine. Bristol-Myers also gains optionality: the ability to pair BNT327 with other in-house experimental compounds. With both firms now locked into a shared bet on combo therapies, this could be a pivotal move in a rapidly shifting oncology landscape. This article first appeared on GuruFocus. Sign in to access your portfolio

Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug

Yahoo

time10 hours ago

  • Yahoo

Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug

Bristol-Myers Squibb (NYSE:BMY) is doubling down on its oncology ambitions with a deal that could reach $11.1 billion, partnering with BioNTech (NASDAQ:BNTX) to co-develop a next-generation cancer therapy known as BNT327. The German biotech will receive $1.5 billion upfront, $2 billion in staggered payments through 2028, and stands to gain another $7.6 billion if clinical and commercial milestones are met. Both companies will share development costs and future profits. The deal reflects growing urgency among pharma giants to replenish their pipelines, as legacy blockbusters face generic competition. Bloomberg Intelligence estimates this class of immunotherapy drugs could generate $60 billion annually by 2027. BNT327's backstory adds intrigue. BioNTech originally licensed the compound from Chinese biotech Biotheus in 2023 before acquiring the company outright for up to $950 million. It's now positioning the therapy as a core asset in its oncology portfolio. While early trial data suggests Pfizer's competing drug may show stronger efficacy, BioNTech is further along in developing broader cancer indications. The approach behind these drugs is evolving fastmerging immunotherapy with anti-angiogenesis mechanisms to cut off tumors' blood and oxygen supply. This model gained traction after Akeso and Summit Therapeutics' combination therapy showed promising results against Merck's Keytruda in a major Chinese trial. Still, the bar remains high. These new therapies haven't yet demonstrated a consistent survival advantage over standard treatments, and head-to-head data outside China could take years. For BioNTech, though, this deal marks a decisive return to its original focuscancerafter riding a pandemic-era wave with its COVID-19 vaccine. Bristol-Myers also gains optionality: the ability to pair BNT327 with other in-house experimental compounds. With both firms now locked into a shared bet on combo therapies, this could be a pivotal move in a rapidly shifting oncology landscape. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store